ERS 2026: oral IRAK4 inhibitor AZD6793 enters dose-ranging Phase IIb COPD trial
At the European Respiratory Society (ERS) Congress 2026, investigators from AstraZeneca and collaborating institutions presented the company's Phase IIb PRESTO …
Post
-
-
AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win
AbbVie’s preventative migraine therapy, Qulipta (atogepant), has netted a successful late-stage readout in menstrual migraine, potentially poising the drug for …
-
TenNor reports top-line Phase IIa results for rifaquizinone in PJI
TenNor Therapeutics has reported positive top-line data from a Phase IIa trial assessing its drug candidate, rifaquizinone (TNP-2092), in patients …
-
Biohaven’s epilepsy drug hit with FDA clinical hold
The US Food and Drug Administration (FDA) has placed a partial clinical hold on the pivotal trials evaluating Biohaven’s epilepsy …
-
First healthy volunteers dosed in Bionyra’s Phase I BYN-001 study
Bionyra Pharma has dosed the first healthy volunteers in a Phase I trial of BYN-001, its long-acting anti-IL-25 monoclonal antibody, which …
-
Podcast: Beyond AI: Why patient-centric clinical trials matter now
Research driving the development of new treatments involves several stakeholders: research coordinators, contract research organisations (CROs), and, most importantly, patients, …
-
ERS 2026: Brensocatib cuts NCFB exacerbations in NTM history patients
On September 6, at the European Respiratory Society (ERS) Congress 2026, Insmed presented results from a post hoc analysis from …
-
ERS 2026: Sanofi’s lunsekimig hits Phase IIb goals in asthma, Phase III set to follow
On September 7, during the European Respiratory Society (ERS) Congress in Barcelona, Sanofi presented detailed efficacy and safety data from …
-
ERS 2026: Phase Ib/IIa results support further evaluation of 9MW1911 in COPD
At the European Respiratory Society (ERS) Congress 2026, Mabwell and collaborating institutions presented results from the Phase Ib/IIa 9MW1911 study …
-
BioMarin paints picture of dwarfism drug’s wider efficacy on Phase III win
BioMarin has debuted new data from a Phase III trial on its dwarfism drug, Voxzogo (vosoritide), which the company hopes …
-
Beeline Medicines’ Phase II SLE trial of afimetoran meets primary endpoint
Beeline Medicines has announced that its global Phase II clinical trial involving adults with active moderate-to-severe systemic lupus erythematosus (SLE), …
-
Tyra announces initial data from Phase II SURF302 trial of dabogratinib
Tyra Biosciences has reported initial data from its Phase II SURF302 clinical trial of the oral drug dabogratinib in FGFR3-altered …
-
Pharma’s R&D, commercial approach shifts amid global policy evolution
A new report from business management consultancy, Numerof & Associates has found that pharma executives are increasingly rethinking the launch …
-
ERS 2026: tozorakimab’s groundbreaking exacerbation reduction sets a new bar in COPD
On September 8, at the European Respiratory Society (ERS) Congress in Barcelona, AstraZeneca presented full results from its Phase III …
-
Pharvaris charts approval course for swelling disorder drug on Phase III win
Swiss biopharma company Pharvaris will file for US approval of deucrictibant XR in the rare swelling disorder hereditary angioedema (HAE), …
